Rigel Pharmaceuticals (NASDAQ: RIGL) net income
Rigel Pharmaceuticals reported a net profit of $367.0m for fiscal 2025, 1,999.1% more than in fiscal 2024 ($17.5m). Its net margin was 124.7%. Earnings per share were $20.40.
Fiscal 2025 is the highest of the 10 fiscal years on record for Rigel Pharmaceuticals. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $367.0m | +1,999.1% | 124.7% | $20.40 |
| 2024 | $17.5m | — | 9.8% | $0.99 |
| 2023 | −$25.1m | — | −21.5% | −$0.14 |
| 2022 | −$58.6m | — | −48.7% | −$0.34 |
| 2021 | −$17.9m | — | −12.0% | −$0.11 |
| 2020 | −$29.7m | — | −27.4% | −$0.18 |
| 2019 | −$66.9m | — | −112.8% | −$0.40 |
| 2018 | −$70.5m | — | −158.3% | — |
| 2017 | −$78.0m | — | −1,739.3% | — |
| 2016 | −$69.2m | — | −339.6% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Rigel Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Rigel Pharmaceuticals ranks 70th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Rigel Pharmaceuticals, 124.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 68th | Acadia Pharmaceuticals | $391.0m | 36.5% |
| 69th | Cooper Companies | $374.9m | 9.2% |
| 70th | Rigel Pharmaceuticals | $367.0m | 124.7% |
| 71st | BioMarin Pharmaceutical | $348.9m | 10.8% |
| 72nd | Ensign Group | $344.0m | 6.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Rigel Pharmaceuticals
- How much did Rigel Pharmaceuticals earn in fiscal 2025?
- Rigel Pharmaceuticals reported a net profit of $367.0m for fiscal 2025. In fiscal 2024 it reported a net profit of $17.5m.
- What are the earnings per share of Rigel Pharmaceuticals?
- They were $20.40 in fiscal 2025, compared with $0.99 in fiscal 2024.
- What is the net margin of Rigel Pharmaceuticals?
- In fiscal 2025 its net profit was 124.7% of its revenue.
- What was the most profitable year for Rigel Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $367.0m.
- Where does Rigel Pharmaceuticals rank in its sector by net income?
- It ranks 70th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Rigel Pharmaceuticals come from?
- From the annual report (Form 10-K) that Rigel Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Rigel Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Rigel Pharmaceuticals: the Rigel Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.